Amarin Corporations Public Company Limited
Amarin Corporation Public Company Limited, commonly referred to as Amarin, is a prominent player in the biopharmaceutical industry, headquartered in Thailand. Founded in 1985, the company has established itself as a leader in the development and commercialisation of innovative therapies, particularly in the cardiovascular sector. With a strong focus on research and development, Amarin's flagship product, Vascepa, is renowned for its unique formulation aimed at reducing cardiovascular risk. The company operates primarily in Thailand and has expanded its reach to various international markets, solidifying its position as a key contributor to global health. Notable achievements include significant advancements in clinical research and a commitment to improving patient outcomes, which have positioned Amarin as a trusted name in the biopharmaceutical landscape.
DitchCarbon Score
How does Amarin Corporations Public Company Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Media Production industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amarin Corporations Public Company Limited's score of 25 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amarin Corporations Public Company Limited's reported carbon emissions
Amarin Corporations Public Company Limited, headquartered in Thailand, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a current subsidiary of Amarin Corporations Public Company Limited, any potential climate commitments or emissions data may be inherited from the parent company. However, no specific initiatives or targets have been identified at this time. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction strategies. While Amarin has not disclosed its own commitments, it is essential for organisations in this sector to align with industry standards and best practices to address climate change effectively.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amarin Corporations Public Company Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
